Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TDF

European Commission forms €2.5bn big data partnership

Says mastering data will lead to better health outcomes

- PMLiVE

FDA approves Olysio/Sovaldi combination in hep C

Janssen drug recommended for use along with Gilead’s blockbuster

- PMLiVE

117,000 hepatitis C patients receive Sovaldi so far

Breakthrough drug has made $8.5bn for Gilead this year

EU flag

EC: medicines to remain part of health directorate

Juncker U-turns on decision to move pharma oversight to enterprise and industry

Gilead Sciences

Gilead gets US approval for Sovaldi follow-up Harvoni

Company claims it could cure 90 percent of patients within eight weeks

- PMLiVE

EMA draws fire on new clinical reports policy

Has recently come under pressure from transparency groups

EU flag

EMA backs 15 new medicines for use in EU

Includes new treatments from Gilead, Lilly, Boehringer, AstraZeneca and Janssen

- PMLiVE

Gilead will file safer HIV combination before year-end

New version of Stribild is less likely to cause side effects

EU flag

EC slammed for pharma oversight changes

Organisations criticise decision to transfer responsibility for pharma policy from health to industrial department

European Commissioner for health and food safety elected

Vytenis Andriukaitis will take on the role from October

- PMLiVE

BMS can ride on Sovaldi’s success as Daklinza cleared in EU

Hepatitis C drug approved in combination with Gilead’s huge-selling treatment

- PMLiVE

NICE backs Gilead’s Sovaldi in hepatitis C

But health watchdog denies earlier use of Janssen’s Zytiga

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links